Brentuximab vedotin (INN, trade name Adcetris) is an antibody-drug conjugate (ADC) used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T cell non-Hodgkin lymphoma)...Wikipedia

 

 

Manufacturer's Website: Adcetris                                                                                                         Average retail cost: $74,903/month

Search Terms: Adcetris, brentuximab vedotin, Hodgkin lymphoma, HL, systemic anaplastic large cell lymphoma, ALCL